Literature DB >> 2812507

Chronic nicotine treatment eliminates asymmetry in striatal glucose utilization following unilateral transection of the mesostriatal dopamine pathway in rats.

C Owman1, K Fuxe, A M Janson, J Kåhrström.   

Abstract

Partial hemitransection was performed through a knife lesion at the meso-diencephalic level in rats to sever the mesostriatal dopamine system. During the subsequent 2 weeks the animals received 0.125 mg/kg/h of nicotine continuously via an osmotic minipump implanted s.c. To achieve prompt high nicotine levels, 4 i.p. injections of 0.5 mg/kg nicotine were, in addition, given during the first 2 h following the lesion. The total treatment corresponded to a mean plasma level of 50 ng/ml nicotine, measured at the end of the experiment. Control animals received corresponding volumes of 0.9% saline. Quantitative autoradiographic analysis of the glucose utilization in the caudate nucleus using Sokoloff's [14C]2-deoxyglucose method demonstrated a 16% side-to-side difference in the lesioned control animals, whereas the asymmetry was counteracted by the nicotine treatment. Although there was an overall tendency to a lower rate of glucose utilization (by 6%) in the nicotine-treated animals compared to the controls receiving saline only, the difference was not statistically significant. The eliminated asymmetry probably reflects an increased survival of the dopamine neurons and/or of striatal nerve cells on the lesioned side due to protective effects of nicotine resulting from desensitization of nicotinic-type cholinergic receptors following continuous administration of the drug.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2812507     DOI: 10.1016/0304-3940(89)90092-x

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  5 in total

1.  Chronic nicotine treatment increases dopamine levels and reduces dopamine utilization in substantia nigra and in surviving forebrain dopamine nerve terminal systems after a partial di-mesencephalic hemitransection.

Authors:  K Fuxe; A M Janson; A Jansson; K Andersson; P Eneroth; L F Agnati
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-03       Impact factor: 3.000

2.  Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice.

Authors:  R E Ryan; S A Ross; J Drago; R E Loiacono
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

3.  Developmental nicotine exposure induced alterations in behavior and glutamate receptor function in hippocampus.

Authors:  Kodeeswaran Parameshwaran; Manal A Buabeid; Senthilkumar S Karuppagounder; Subramaniam Uthayathas; Karikaran Thiruchelvam; Brian Shonesy; Alexander Dityatev; Martha C Escobar; Muralikrishnan Dhanasekaran; Vishnu Suppiramaniam
Journal:  Cell Mol Life Sci       Date:  2011-10-28       Impact factor: 9.261

4.  The short-term effect of nicotine chewing gum in patients with Parkinson's disease.

Authors:  P Clemens; J A Baron; D Coffey; A Reeves
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

Review 5.  Developmental cholinotoxicants: nicotine and chlorpyrifos.

Authors:  T A Slotkin
Journal:  Environ Health Perspect       Date:  1999-02       Impact factor: 9.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.